Health Canada endorsed important safety information on REVLIMID (lenalidomide)

Subject: Association of REVLIMID® (lenalidomide) with an increased risk of second primary malignancies REVLIMID® is an antineoplastic and immunomodulatory agent indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities (approval was based on a surrogate marker of transfusion independence). REVLIMID® is also indicated in combination with dexamethasone for the treatment of multiple myeloma (MM) in patients who have received at least one prior therapy. See the full letter from Drugs and Health Products - Health Canada.